Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight increase, with significant net inflows from institutional and retail investors, indicating positive market sentiment towards the company [1][2]. Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, a year-on-year increase of 6.63% [2] - The net profit attributable to the parent company was 260 million yuan, up 3.3% year-on-year [2] - The net profit after deducting non-recurring items was 222 million yuan, reflecting a 1.46% increase year-on-year [2] - In Q3 2025, the company achieved a single-quarter revenue of 902 million yuan, a significant year-on-year increase of 30.72% [2] - The single-quarter net profit attributable to the parent company was approximately 92.83 million yuan, up 38.68% year-on-year [2] - The single-quarter net profit after deducting non-recurring items was about 85.80 million yuan, marking a 62.68% increase year-on-year [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan [2] - The gross profit margin is reported at 53.35% [2] Market Activity - As of February 13, 2026, Kefu Medical's stock closed at 56.25 yuan, with a trading volume of 22,300 hands and a total transaction amount of 126 million yuan [1] - The net inflow of main funds was 11.15 million yuan, accounting for 8.88% of the total transaction amount [1] - Retail investors experienced a net outflow of 16.53 million yuan, representing 13.16% of the total transaction amount [1] - Over the past 90 days, six institutions have provided ratings for the stock, with five buy ratings and one hold rating [2] - The average target price set by institutions in the last 90 days is 5.492 yuan [2]
股票行情快报：可孚医疗（301087）2月13日主力资金净买入1115.30万元